Betrixaban hydrochloride(330942-05-7(free base))

SKU: orb1302649

Description

Betrixaban hydrochloride (CAS 330942-05-7 for the free base), also known as PRT054021 hydrochloride, is a potent and selective oral factor Xa inhibitor with an IC50 of 1.5 nM. It has been utilized in research models investigating thrombosis and anticoagulation, demonstrating efficacy in both in vitro enzymatic assays and in vivo preclinical studies.

Research Area

Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• MW: 488.36
• Purity: 99.54% (May vary between batches)
• Formula: C₂₃H₂₃Cl₂N₅O₃
• SMILES: Cl.COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1
• Target: Factor Xa
• Solubility: DMSO:20 mg/mL (40.95 mM)

Bioactivity

• Target IC50:
  FXa:1.5 nM
• In Vivo:
  Betrixaban (0.5 mg/kg, i.v. and 2.5 mg/kg, p.o.) has bioavailability of 51.6% in dog; dosed at 0.75 mg/kg IV and 7.5 mg/kg PO, Betrixaban has bioavailability of 58.7% in monkey. Both Betrixaban and Apixa-ban-mediated whole-blood INR increases are similarly reversed by r-Antidote. After i.v. infusion of the three fXa inhibitors (each admin istered individually) for 30 min, the total plasma concentrations of rivaroxaban, Betrixaban and apixaban are 1.4±0.4 μM (mean±s.d.), 0.2±0.01 μM and 1.4±0.3 μM, respectively, and the percentages of unbound inhibitor are 2.2%±0.8% (mean±s.d.), 40%±7.2% and 1.5%±0.3%, respectively. After administration of r-Antidote, the total plasma concentrations of the inhibitors increased to 1.9±0.09 μM, 2.0±0.4 μM and 4.2±0.7 μM, respectively, and the percentage of unbound inhibitor declined to 0%, 0.3%±0.1% and 0.05%±0.02%, respectively. Thus, for each of the three inhibitors, correction of prothrombin time by r-Antidote to near-normal values is associated with a reduction in the free fraction of the inhibitor.
• In Vitro:
  In patch clamp hERG assays, Betrixaban has IC50 of 8.9 μM. The plasma kallikrein IC50 and Ki values for Betrixaban are 6.3 μM and 3.5 μM respectively. Betrixaban (hERG Ki 1.8 μM) exhibits significantly lower hERG activity than all the others (hERG Ki 0.5 μM).

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PRT054021 hydrochloride, PRT054021 Hydrochloride, PRT-054021 Hydrochloride, PRT 054021 Hydrochloride, Betrixaban hydrochloride(330942 05 7(free base)), Betrixaban hydrochloride(330942057(free base)), Betrixaban hydrochloride(330942-05-7(free base)), Factor Xa, FactorXa

Compound Identifiers

PubChem CID

16717958